EP Patent

EP4599831A1 — Treatment of gastroparesis with tradipitant

Assigned to Vanda Pharmaceuticals Inc · Expires 2025-08-13 · 1y expired

What this patent protects

Disclosed herein is tradipitant for use in the treatment of an individual suffering from gastroparesis or delayed gastric emptying. In an embodiment, the treatment method comprises administering to the individual tradipitant at a dose of 150-400 mg/day, wherein the individual has…

USPTO Abstract

Disclosed herein is tradipitant for use in the treatment of an individual suffering from gastroparesis or delayed gastric emptying. In an embodiment, the treatment method comprises administering to the individual tradipitant at a dose of 150-400 mg/day, wherein the individual has a genetic sequence containing a variant allele in a gene selected from the group consisting of SLC4A4, SDK2, LCLATI, SLC25A16, and CNTN1.

Drugs covered by this patent

Patent Metadata

Patent number
EP4599831A1
Jurisdiction
EP
Classification
—
Expires
2025-08-13
Drug substance claim
No
Drug product claim
No
Assignee
Vanda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.